Sep 27, 2018 10:00 AM

Author: Stacy W. Kish


Floyd Hare

It all started during a routine doctor’s visit.

“My doctor held the stethoscope to my neck,” begins Floyd Hare. “It was weird. He had never done that before.”

But it was a good thing. The doctor was listening to Floyd’s carotid arteries, the two major blood vessels that supply oxygenated blood to the brain. The doctor did not like what he heard. 

Following a sonogram of the carotid arteries, Larry Kraiss, MD, chief of Vascular Surgery Clinic at University of Utah Health had to deliver the difficult news. Both of Floyd’s carotid arteries were clogged — 70 percent clogged.

A further MRI and a brain scan revealed dark spots — portions of Floyd’s brain tissue had died during small strokes. 

“Physically I felt fine. I have never experienced any symptoms of a stroke,” Floyd said. “When [my doctors] told me I was a candidate for a major stroke, I won’t lie. It scared me.” 

Consent in a Crisis: Every Second Counts

The doctor’s presented Floyd with an opportunity — participation in the CREST-2 clinical trial to help himself as well as other potential stroke patients in his home state of Utah and across the nation. 

CREST-2 is one of a series of trials managed by StrokeNet, a clinical trials network funded through the National Institutes of Health to advance the study of stroke treatment, prevention, and recovery available to patients across the country.

“StrokeNet allows us to bring clinical trials to the people rather than the people to the trials,” said Jennifer Majersik, MD, associate professor of Neurology at U of U Health and principle investigator for the Utah StrokeNet regional center. Utah StrokeNet coordinates clinical trials conducted at nine stroke centers in three states across the Mountain West. 

These trials are vital to improve prevention and treatments, but Majersik sees the stress that stroke patients and their caregivers experience when they arrive at the emergency room. When a stroke happens, a patient has about a three-hour window to receive care. In this compressed timeframe, doctors have to rapidly explain the ins and outs of a clinical trial to eligible patients, a requirement when enrolling in a study. 

What is a placebo? A placebo is not a sugar pill and does not mean no treatment. For each clinical trial, placebo patients receive standard or above standard practice of care. Placebos are required in order to know if the new treatment provides any advantage or harm beyond that of standard care.  What is randomization? Randomization ensures that a mix of people are evenly split between the two groups in the studythose that receive the new treatment and those who receive the standard course of treatment (placebo). This approach eliminates any bias in the study so the trial results are meaningful.   What is blinding? Blinding shields the patient and sometimes the clinician from knowing who in the study is receiving a new treatment versus the placebo. It prevents conscious or unconscious bias from affecting the study design and execution.  For safety reasons, clinicians can lift the study blind and return the patient to the standard course of treatment.
Key points to know about joining a clinical trial

“Patients hit the hospital and they have a lot to deal with,” said Majersik. “Trying to get consent for a clinical trial is like teaching someone how to read while they are having a stroke.” 

She wants to provide potential patients, family, caregivers, and surrogates a better understanding of the key points of clinical trials, like placebo, randomization, and blinding. A basic understanding of this information will reduce the burden of information overload on patients and their family when they arrive at the hospital during a time of crisis.

When considering joining the clinical trial, Floyd had an advantage over other StrokeNet patients. He had not yet experienced the catastrophic event that could debilitate and even kill. He had time — time to implement changes that could extend his life.

Taking the Plunge

Floyd thought over his options and decided to take his care team’s recommendation, joining CREST-2 in July 2015.

“In all honesty when I found out about the program at the U, I was hoping that I could become a member of the trial,” Floyd said. “I know the reputation of the U. It’s one of the best hospitals in the country.” 

CREST-2 focuses on patients whose carotid artery narrows as plaque deposits accumulate. Patients are left susceptible to strokes and temporary strokes (transient ischemic attack), which can cause paralysis, numbness, vision loss, or inability to speak.

I wasn’t worried that [the clinical trial] would harm me, but I was worried whether it would help me for the first little bit,” Floyd said. “The doctors here are so good it took all that fear away for me.”

Patients enrolled in CREST-2 are randomly assigned to one of three groups to compare treatments for management of stroke prevention.  The non-intervention group (placebo) receives standard treatment, consisting of medications to reduce blood clots, lower blood pressure, and reduce bad cholesterol. They also work with a life coach to learn new ways to incorporate a healthy lifestyle into their daily activities, a benefit generally not available to most stroke patients. The other two groups receive the same care as the non-intervention group as well as have their carotid artery opened by either surgical removal of plaque or carotid stenting. 

CREST-2 is currently enrolling participants  at multiple hospitals in Utah and is seeking patients who are 35 years or older, have a narrowing of the carotid artery (by 70 percent), and lack other serious medical complications. For information on how to become a participant as well as trial details, contact the UT StrokeNet at 801-581-5523.

Floyd was selected for the non-intervention group. After two years taking the prescribed medications and maintaining a healthy lifestyle, his right carotid artery had not stabilized.

“The left side was doing good,” Floyd said. “The medication was not working well on the right side. It was getting worse.”

His care team decided it was time to surgically clean the plaque from his right artery. Today, his right carotid artery has minimal blockage and his left artery remains stable. 

How does Floyd feel about being a medical pioneer?

I never really thought about it in all honesty,” Floyd said with a chuckle. “I accepted this as something I had to do if I wanted to stay on Earth a little longer.”

F – Facial weakness A – Arm weakness S – Speech problems T – Time to call.
At the first sign of stroke, remember to act FAST.

Know the Signs of Stroke

According to Majersik, you can make a difference by simply understanding the symptoms of stroke and knowing how to respond. At the first sign of stroke, remember to act FAST. 

F – Facial weakness

A – Arm weakness

S – Speech problems

T – Time to call.  

“Time really is of the essence,” Majersik said. “Patients and family members should call 911 immediately if they have any signs or symptoms of stroke.”

A healthy lifestyle can also be one of the best lines of defense against stroke. 

"Not only is high blood pressure one of the leading risk factors for stroke, but it is also one of the most controllable risk factors, as well," said Majersik.


Stacy W. Kish

Stacy is a science writer with University of Utah Health

Research News Stroke

Archives By Year